Ipsen Pty Ltd

31 PBAC submissions on file, active 2005–2025. 84% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Cabozantinib
  Oncology · Not recommended · 2025—
• Lanreotide
  Endocrinology · Recommended with restriction · 2024—
• Clostridium botulinum type a toxin-haemagglutinin complex
  Neurology · Recommended with restriction · 2020—
• Lanreotide acetate
  Endocrinology · Recommended with restriction · 2017—
• Mecasermin
  Endocrinology · Deferred · 2022—
• Odevixibat
  Hepatology · Recommended with restriction · 2025—
• Triptorelin
  Endocrinology · Recommended with restriction · 2021—
• Clostridium botulinum type a toxin haemagglutinin complex
  Neurology · Recommended with restriction · 2011—
• Clostridium botulinum type a toxin – haemagglutinin complex
  Neurology · Recommended with restriction · 2019—
• Elafibranor
  Hepatology · Recommended with restriction · 2025—
• Palovarotene
  Rare disease · Recommended with restriction · 2024—

Therapy area mix

Activity by year

2005 (1) · 2006 (1) · 2007 (1) · 2011 (1) · 2015 (1) · 2016 (1) · 2017 (4) · 2019 (5) · 2020 (3) · 2021 (2) · 2022 (1) · 2023 (1) · 2024 (6) · 2025 (3)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×Unclear place in therapy across requested populations
• 1×inconsistent restrictions compared to nominated comparators (sunitinib
• 1×everolimus)
• 1×inclusion of locally advanced and moderately-differentiated disease with inadequate efficacy data in these subgroups
• 1×absence of ECOG performance status criterion